SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1084)8/13/2009 10:49:19 AM
From: rkrw  Read Replies (1) | Respond to of 1127
 
I have the market cap at closer to $3B now. Either way i don't understand the comparison. Gilead held 100% rights to their compounds, cornering an hiv market, helping to make hiv a chronic instead of a fatal disease. hgsi on the other hand holds 50% of a single drug and the rest of the pipeline is just so-so. So hgsi becoming another gild on this seems far fetched.



To: tuck who wrote (1084)8/13/2009 6:11:22 PM
From: DewDiligence_on_SI  Respond to of 1127
 
Gilead is sui generis (eom).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News